Clinical trial
Efficacy of Vildagliptin 100 MG as Compared to Placebo as Add-on to Metformin in…
NCT00351884 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00351884 |
|---|---|
| Title | Efficacy of Vildagliptin 100 MG as Compared to Placebo as Add-on to Metformin in Patients With Type 2 Diabetes |
| Official title | A Multicenter, Double-blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment With Vildagliptin 100 MG QD to Placebo as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | Vildagliptin AM, vildagliptin pm, placebo |
| Enrollment | 370 |
| Start date | May 1, 2006 |
| Primary completion | Nov 1, 2007 |
| First posted | Jul 13, 2006 |
| Last update posted | Nov 18, 2016 |
| Countries | Germany, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: